Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 30;1(2):100037.
doi: 10.1016/j.jtocrr.2020.100037. eCollection 2020 Jun.

Catalog of 5' fusion partners in RET+ NSCLC Circa 2020

Sai-Hong Ignatius Ou  1 , Viola W Zhu  1
Affiliations
Review

Catalog of 5' fusion partners in RET+ NSCLC Circa 2020

Sai-Hong Ignatius Ou et al. JTO Clin Res Rep. .

Abstract

Since the discovery of RET fusion-positive (RET+) NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that RET fusion is an actionable oncogenic driver in NSCLC. There seems to be a differential response to multikinase inhibitors depending on the fusion partner (KIF5B-RET versus non-KIF5B-RET); thus, knowledge of the fusion partners in RET+ NSCLC is important. To date, we identified 48 unique fusion partners in RET from published literature and congress proceedings. Two of the novel fusion partners (CCNYL2 and TRIM24) were identified in RET fusions that emerged as resistant to EGFR tyrosine kinase inhibitors. In addition, multiple intergenic rearrangements were identified.

Keywords: 5′ fusion partners; NSCLC; Pralsetinib; RET; Selpercatinib; Whole-transcriptome sequencing.

PubMed Disclaimer

References

    1. Ju Y.S., Lee W.C., Shin J.Y. Fusion of KIF5B and RET transforming gene in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436–445. - PMC - PubMed
    1. Kohno T., Ichikawa H., Totoki Y. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18:375–377. - PMC - PubMed
    1. Takeuchi K., Soda M., Togashi Y. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378–381. - PubMed
    1. Lipson D., Capelletti M., Yelensky R. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382–384. - PMC - PubMed
    1. Drilon A., Rekhtman N., Arcila M. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016;17:1653–1660. - PMC - PubMed